Literature DB >> 90215

Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

P J Meunier, M C Chapuy, C Alexandre, C Bressot, C Edouard, C Vignon, L Mathieu, U Trechsel.   

Abstract

19 patients with Paget's disease were treated orally for 6 months with disodium dichloromethylene diphosphonate. 1600 mg/day (10 patients) significantly reduced urine hydroxyproline, serum alkaline phosphatase, urine calcium, and the number of pagetic bone osteoclasts. Tetracycline double labelling revealed undisturbed bone mineralisation. There was improvement on quantitative bone-scans and bone pain diminished. There was a transient increase in parathyroid hormone level in 13 of the 19 patients during treatment, which was associated with a high serum 1,25 (OH)2D3. No adverse clinical side-effects have been observed and biochemical remission has persisted for 9 months.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 90215     DOI： 10.1016/s0140-6736(79)91551-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  34 in total

Review 1.  Advances in the management of Paget's disease of bone.

Authors:  D J Hosking
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Hyperostosis induced by the bisphosphonate (2-PEBP) in the oophorectomized rat.

Authors:  C Movsowitz; S Epstein; M Fallon; F Ismail; S Thomas
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

3.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

4.  Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

Authors:  R Schenk; P Eggli; H Fleisch; S Rosini
Journal:  Calcif Tissue Int       Date:  1986-06       Impact factor: 4.333

Review 5.  Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.

Authors:  N van Rooijen
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

6.  Ultrafiltrability and chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylenebisphosphonate in aqueous buffers and in human plasma.

Authors:  W H Wiedmer; A M Zbinden; U Trechsel; H Fleisch
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

Review 7.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

8.  Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

Authors:  P H Reitsma; O L Bijvoet; M Potokar; L J van der Wee-Pals; M M van Wijk-van Lennep
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

9.  Clinical experience with pamidronate in the treatment of Paget's disease of bone.

Authors:  S J Gallacher; B F Boyce; U Patel; A Jenkins; S H Ralston; I T Boyle
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

10.  Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.

Authors:  J A Cantrill; H M Buckler; D C Anderson
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.